skip to content

[Ad hoc announcement pursuant to Art. 53 LR] Roche’s Columvi meets primary endpoint of overall survival in people with relapsed or refractory diffuse large B-cell lymphoma in Phase III STARGLO study

Media

Media releases
view all

stay updated

get the latest news and updates to your inbox.